[1]
Gregori, M.; Masserini, M.; Mancini, S. Nanomedicine for the treatment of Alzheimer’s disease. Nanomedicine (Lond.), 2015, 10(7), 1203-1218.
[2]
Gao, H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm. Sin. B, 2016, 6(4), 268-286.
[3]
Gao, H.; Pang, Z.; Jiang, X. Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm. Res., 2013, 30(10), 2485-2498.
[4]
Gao, H. Perspectives on dual targeting delivery systems for brain tumors. J. Neuroimmune Pharmacol., 2017, 12(1), 6-16.
[5]
Nath, S.; Agholme, L.; Kurudenkandy, F.R.; Granseth, B.; Marcusson, J.; Hallbeck, M. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of beta-amyloid. J. Neurosci., 2012, 32(26), 8767-8777.
[6]
Zhang, C.; Gu, Z.; Shen, L.; Liu, X.; Lin, H. A dual targeting drug delivery system for penetrating blood brain barrier and selectively delivering siRNA to neurons for Alzheimer’s disease treatment. Curr. Pharm. Biotechnol., 2018, 18(14), 1124-1131.
[7]
Zensi, A.; Begley, D.; Pontikis, C.; Legros, C.; Mihoreanu, L.; Buchel, C.; Kreuter, J. Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain. J. Drug Target., 2010, 18(10), 842-848.
[8]
Xie, Y.; Tisi, M.A.; Yeo, T.T.; Longo, F.M. Nerve growth factor (NGF) loop 4 dimeric mimetics activate ERK and AKT and promote NGF-like neurotrophic effects. J. Biol. Chem., 2000, 275(38), 29868-29874.
[9]
Zeng, J.; Too, H.P.; Ma, Y.; Luo, E.S.; Wang, S. A synthetic peptide containing loop 4 of nerve growth factor for targeted gene delivery. J. Gene Med., 2004, 6(11), 1247-1256.
[10]
Allaman, I.; Gavillet, M.; Belanger, M.; Laroche, T.; Viertl, D.; Lashuel, H.A.; Magistretti, P.J. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: Impact on neuronal viability. J. Neurosci., 2010, 30(9), 3326-3338.
[11]
He, Z.; Guo, J.L.; McBride, J.D.; Narasimhan, S.; Kim, H.; Changolkar, L.; Zhang, B.; Gathagan, R.J.; Yue, C.; Dengler, C.; Stieber, A.; Nitla, M.; Coulter, D.A.; Abel, T.; Brunden, K.R.; Trojanowski, J.Q.; Lee, V.M. Amyloid-beta plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med., 2018, 24(1), 29-38.
[12]
Cai, H.; Wang, Y.; McCarthy, D.; Wen, H.; Borchelt, D.R.; Price, D.L.; Wong, P.C. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci., 2001, 4(3), 233-234.
[13]
Zohar, O.; Cavallaro, S.; D’Agata, V.; Alkon, D.L. Quantification and distribution of beta-secretase alternative splice variants in the rat and human brain. Brain Res. Mol. Brain Res., 2003, 115(1), 63-68.
[14]
Vassar, R. Beta-secretase (BACE) as a drug target for Alzheimer’s disease. Adv. Drug Deliv. Rev., 2002, 54(12), 1589-1602.
[15]
Zheng, X.; Zhang, C.; Guo, Q.; Wan, X.; Shao, X.; Liu, Q.; Zhang, Q. Dual-functional nanoparticles for precise drug delivery to Alzheimer’s disease lesions: Targeting mechanisms, pharmacodynamics and safety. Int. J. Pharm., 2017, 525(1), 237-248.
[16]
Hu, G.; Zhang, H.; Zhang, L.; Ruan, S.; He, Q.; Gao, H. Integrin-mediated active tumor targeting and tumor microenvironment response dendrimer-gelatin nanoparticles for drug delivery and tumor treatment. Int. J. Pharm., 2015, 496(2), 1057-1068.
[17]
Zhang, H.; Wu, T.; Yu, W.; Ruan, S.; He, Q.; Gao, H. Ligand size and conformation affect the behavior of nanoparticles coated with in vitro and in vivo protein corona. ACS Appl. Mater. Interfaces, 2018, 10(10), 9094-9103.
[18]
Liu, R.; Xiao, W.; Hu, C.; Xie, R.; Gao, H. Theranostic size-reducible and no donor conjugated gold nanocluster fabricated hyaluronic acid nanoparticle with optimal size for combinational treatment of breast cancer and lung metastasis. J. Control. Release, 2018, 278, 127-139.
[19]
Hu, C.; Cun, X.; Ruan, S.; Liu, R.; Xiao, W.; Yang, X.; Yang, Y.; Yang, C.; Gao, H. Enzyme-triggered size shrink and laser-enhanced NO release nanoparticles for deep tumor penetration and combination therapy. Biomaterials, 2018, 168, 64-75.
[20]
Ruan, S.; Hu, C.; Tang, X.; Cun, X.; Xiao, W.; Shi, K.; He, Q.; Gao, H. Increased gold nanoparticle retention in brain tumors by in situ enzyme-induced aggregation. ACS Nano, 2016, 10(11), 10086-10098.
[21]
Xiao, W.; Xiong, J.; Zhang, S.; Xiong, Y.; Zhang, H.; Gao, H. Influence of ligands property and particle size of gold nanoparticles on the protein adsorption and corresponding targeting ability. Int. J. Pharm., 2018, 538(1-2), 105-111.
[22]
Ruan, S.; Qian, J.; Shen, S.; Chen, J.; Cun, X.; Zhu, J.; Jiang, X.; He, Q.; Gao, H. Non-invasive imaging of breast cancer using RGDyK functionalized fluorescent carbonaceous nanospheres. RSC Advances, 2015, 5(254), 28-36.
[23]
Gao, H.; He, Q. The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior. Expert Opin. Drug Deliv., 2014, 11(3), 409-420.
[24]
Gao, H.; Yang, Z.; Zhang, S.; Pang, Z.; Jiang, X. Internalization and subcellular fate of aptamer and peptide dual-functioned nanoparticles. J. Drug Target., 2014, 22(5), 450-459.
[25]
Gao, H.; Yang, Z.; Zhang, S.; Cao, S.; Shen, S.; Pang, Z.; Jiang, X. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci. Rep., 2013, 3, 2534.
[26]
Liu, J.; Shapiro, J.I. Endocytosis and signal transduction: basic science update. Biol. Res. Nurs., 2003, 5(2), 117-128.
[27]
Gao, H.; Xiong, Y.; Zhang, S.; Yang, Z.; Cao, S.; Jiang, X. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol. Pharm., 2014, 11(3), 1042-1052.
[28]
Ruan, S.; Qin, L.; Xiao, W.; Hu, C.; Zhou, Y.; Wang, R.; Sun, X.; Yu, W.; He, Q.; Gao, H. Acid-responsive transferrin dissociation and GLUT mediated exocytosis for increased blood-brain barrier transcytosis and programmed glioma targeting delivery. Adv. Funct. Mater., 2018, 28(30), 1802227.
[29]
Pang, Z.; Lu, W.; Gao, H.; Hu, K.; Chen, J.; Zhang, C.; Gao, X.; Jiang, X.; Zhu, C. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J. Control. Release, 2008, 128(2), 120-127.
[30]
Zhang, C.; Chen, J.; Feng, C.; Shao, X.; Liu, Q.; Zhang, Q.; Pang, Z.; Jiang, X. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer’s disease. Int. J. Pharm., 2014, 461(1-2), 192-202.
